Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients’ Profiles with Dynamic Mathematical Models
出版年份 2020 全文链接
标题
Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients’ Profiles with Dynamic Mathematical Models
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-14
DOI
10.1002/cpt.1942
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
- (2019) Carlo Capalbo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Are innovation and new technologies in precision medicine paving a new era in patients centric care?
- (2019) Attila A. Seyhan et al. Journal of Translational Medicine
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
- (2019) Neta Tsur et al. Journal of Translational Medicine
- Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug
- (2019) D. Perlstein et al. PLoS One
- Precision Medicine: Functional Advancements
- (2018) Thomas Caskey Annual Review of Medicine
- Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
- (2018) Kim A. Brogden et al. BMC CANCER
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
- (2017) Stéphane Oudard et al. JOURNAL OF CLINICAL ONCOLOGY
- Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
- (2017) Shumei Kato et al. Journal of the National Comprehensive Cancer Network
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC): Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel
- (2017) M Schwager et al. VALUE IN HEALTH
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
- (2017) Giulia Viale et al. Biomed Research International
- Utilizing selection biomarkers in clinical trials: is this the future of drug development?
- (2016) Adam Carroll Biomarkers in Medicine
- Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy
- (2016) U. Foryś et al. JOURNAL OF MATHEMATICAL BIOLOGY
- Precision oncology: origins, optimism, and potential
- (2016) Vinay Prasad et al. LANCET ONCOLOGY
- The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer
- (2016) Hu Ma et al. MEDICINE
- A federated ecosystem for sharing genomic, clinical data
- (2016) SCIENCE
- PD-L1 Expression as a Predictive Biomarker
- (2016) Feriyl Bhaijee et al. JAMA Oncology
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
- (2016) Kevin K. Dobbin et al. Journal for ImmunoTherapy of Cancer
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies
- (2013) Zinnia P. Parra-Guillen et al. AAPS Journal
- Reconsidering the Paradigm of Cancer Immunotherapy by Computationally Aided Real-time Personalization
- (2012) Y. Kogan et al. CANCER RESEARCH
- Mathematical Modeling in Immunotherapy of Cancer: Personalizing Clinical Trials
- (2012) Zvia Agur et al. MOLECULAR THERAPY
- Personalizing immunotherapy
- (2012) Zvia Agur et al. OncoImmunology
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers
- (2011) Moran Elishmereni et al. PLoS Computational Biology
- Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models
- (2010) Raluca Eftimie et al. BULLETIN OF MATHEMATICAL BIOLOGY
- From the evolution of toxin resistance to virtual clinical trials: the role of mathematical models in oncology
- (2010) Zvia Agur Future Oncology
- Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models
- (2010) Natalie Kronik et al. PLoS One
- Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: A New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model
- (2008) Boris Gorelik et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation